The International Myeloma Working Group (IMWG) has published dozens of research studies and treatment guidelines on multiple myeloma and its related disorders. The following are a sample of the International Myeloma Working Group’s ranging publication topics:

  • Genetic predisposition for chemotherapy-induced neuropathy in multiple myeloma
  • Gene signature combinations improve prognostic stratification of multiple myeloma patients
  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study
  • Combining Fluorescent In Situ Hybridization (iFISH) data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group (IMWG) collaborative project

From doctors to patients, the goal of these publications is to help anyone better understand aspects of myeloma. The information provided in the International Myeloma Working Group’s publications seeks to help guide patients and their doctors to treating myeloma in the most effective way for every individual case.





The IMWG presents new diagnostic criteria for multiple myeloma along with definitions of related plasma cell proliferative disorders.









The IMWG’S guidelines for diagnostic and specialty services required to support treatment decision-making and patient management.









The following guidelines highlight potential uses of the serum free light chain, which have proven their utility, and which are undergoing investigation.









This study explores the available drugs, health care systems, coverage of new agents, old drugs, and more in Latin American Countries.


Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.